We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Regenerative Technology Treats Acute and Chronic Wounds

By HospiMedica International staff writers
Posted on 11 Feb 2020
An allograft made of dehydrated human umbilical cord tissue serves as a barrier membrane over acute and chronic wounds.

The StimLabs (Roswell, GA, USA) Corplex allograft is intended to facilitate the repair, reconstruction, replacement, or supplementation of injured tissue, by providing a robust matrix and protective barrier during wound remodeling. More...
It is supplied in a sheet format for use in patients with chronic or acute wounds, especially tunneling wounds where a thicker sheet is warranted. Corplex complements StimLabs' portfolio of products, which includes Ascent, made of dehydrated cells and cellular components retained from amniotic fluid in an injectable format; and Revita, an intact human placental membrane allograft that preserves all layers of the native tissue in a shelf-stable format.

Corplex preserves structural umbilical cord tissue constituents using StimLabs’ patent-pending Clearify process, which retains key extracellular matrix (ECM) components, such as collagens, proteoglycans, and glycosaminoglycans, from both the epithelial layer and the Wharton's Jelly section of the umbilical cord tissue, while effectively cleaning and terminally sterilizing the graft. Corplex is shelf-stable for up to five years and is offered in various sheet sizes (15 mm, 2x2 cm, 2x3 cm, and 3x5 cm).

“Since StimLabs' inception, it's been our promise to deliver more targeted approaches to influence healing through accessibility, ease of use, and effectiveness, to ultimately improve patient outcomes,” said Sarah Griffiths, PhD, VP of Research and Development at StimLabs. “We've worked diligently to ensure these patent-pending processes and products are another step towards that aspiration. We're excited to continue pushing our product portfolio boundaries to more effectively meet the needs of both patients and providers.”

The umbilical cord (UC) is an essential part of the placenta, forming within the first weeks of gestation by the enclosure of blood vessels into a bulk of mucous connective tissue, named Wharton's jelly, and lined by the umbilical epithelium. The cells populating each component of the cord--Wharton's jelly, the lining epithelium, the sub-amnion layer, the perivascular region, and the blood vessels--are a reservoir of progenitor populations which are collectively grouped as mesenchymal stem cells (MSCs), which can differentiate towards mature cell types belonging to all the three germ layers.

Related Links:
StimLabs


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.